Skip to main content

Table 3 Summary of the similar studies on aflibercept treatment in resistant AMD cases

From: Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD

Study group

No of eyes

Mean age

No of previous injections

No of Afl injections

Mean follow-up time (month)

Visual acuity (LogMAR)

CMT (micron)

Before Afl

After Afl

Before Afl

After Afl

Cho et al.1

28

80,68 (62-95)

20,2±7,6 (7-37)

4,4 (3-6)

171 (134–192) days

0,52

0,57

295

274

Bakall et al.2

36

79 (60-88)

25,6±(6-74)

5,2 (4-6)

6

0,45

0,50

410 (174-1027)

296 (151-528)

Ho et al 3

96

79 (62-91)

17 (1-60)

2,6 (2-4)

114 (90-133) days

20/50 (snellen)

0,02 (LogMAR)

276 (130-559)

258 (198-242)

Yonekawa et al 4

102

79,6 (57-93)

20,4 (3-65)

3,8 (1-8)

18,4 weeks

0,42

0,38

305,07

276,20

Kumar et al 5

34

79 (72-84)

28,6 (10-47)

5,3 (5-6)

6,5 (6-6,6)

0,57

0,47

416±217

348±171

Hall et al 6

30

80,4 (-)

14,9 (2-53)

6,27 (4-11)

10,4 (3-12)

0,533*

0,521*

264±12,5*

237±10,2*

Heussen et al 7

71

77 (43-95)

9 (3-43)

2,7 (1-4)

-

0,56+

0,43+

350.8±115+

260.8±34+

  1. *values of 22 eyes with 12 moths follow-up period.
  2. +values of 45 eyes which had 3 aflibercept injections.
  3. Afl: Aflibercept, CMT: Central macular thickness.
  4. 1 Cho H, Shah CP, Weber M, Heier JS. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol 2013;97(8):1032-5.
  5. 2 Bakall B, Folk JC, Boldt HC, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol. 2013;156(1):15-22.
  6. 3 Ho VY, Yeh S,olsen TW, et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor ınhibitors. Am J Ophthalmol. 2013;156(1):23-28.
  7. 4 Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013;156(1):29-35.
  8. 5 Kumar N, Marsiglia M, Mrejen S, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 2012;33:1605–1612.
  9. 6Hall LB, Zebardast N, Huang JJ and Adelman RA. Aflibercept in the treatment of neovascular age-related Macular degeneration in previously treated patients. J Ocul Pharmacol Ther. DOI: 10.1089/jop.2013.0188.
  10. 7 Heussen FM, Shao Q, Ouyang Y et al. Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol DOI 10.1007/s00417-013-2553-7.
Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us